EUCTR2010-022653-41-IT进行中（未招募）不适用
Phase II study of neoadjuvant cisplatin and gemcitabine plus sorafenib for patients with transitional cell carcinoma of the bladder. - Sorafenib-CG in TCC of the bladder
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2010年11月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age =18 years. 2. ECOG Performance Status of at least 1. 3. Confirmation of TCC histology by trans-urethral resection of the bladder (TURB). 4. Confirmation of muscle-invasive (T=2) disease at TURB or clinical stage T3 and T4 (e.g. T2 patients will not be eligible without an histological documentation of invasive disease). Confirmation of TCC histology based on pathologic review at Fondazione INT Milan will be required in all cases. 5. Clinically node-negative (cN0) disease. 6. No prior systemic therapies (patients who received intravesical therapy for superficial disease will be eligible). 7. No prior therapy with sorafenib and no use of any investigational agents within 4 weeks of study entry. 8. Subjects must provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Documentation of nodal or distant metastatic disease. 2. Urothelial carcinoma of the upper urinary tract. 3. Prior malignancy. NOTE: Subjects who have had another malignancy and have been disease-free for 5 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible. 4. Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding including, but not limited to: - Active peptic ulcer disease - Known intraluminal metastatic lesion/s with suspected bleeding - Inflammatory bowel disease (e.g. ulcerative colitis, Chrohn’s disease), or other gastrointestinal conditions with increased risk of perforation - History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess within 28 days prior to beginning study treatment. 5. Clinically significant gastrointestinal abnormalities that may increase the risk of bleeding or may affect absorption of investigational product including, but not limited to: - Malabsorption syndrome - Major resection of the stomach or small bowel. 6. Presence of uncontrolled infection (grade >2 NCI-CTC version 4.0). 7. Prolongation of corrected QT interval (QTc) > 450 msecs. 8. History of any one or more of the following cardiovascular conditions within the past 6 months. - Cardiac angioplasty or stenting. - Myocardial infarction. - Unstable angina. - Coronary artery by-pass graft surgery. - Symptomatic peripheral vascular disease. - Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA). 9. Poorly controlled hypertension [defined as systolic blood pressure (SBP) of =140 mmHg or diastolic blood pressure (DBP) of = 90mmHg]. NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. The mean SBP/DBP values from each blood pressure assessment must be <140/90mmHg in order for a subject to be eligible for the study. 10. History of cerebrovascular accident, pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months. 11. Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major). 12. Evidence of active bleeding or bleeding diathesis. 13. Substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results. 14. Any condition that is unstable or could jeopardize the safety of the patients and their compliance in the study. 15. Patients unable to swallow oral medications. 16. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drug chemically related to study drug. 17. Patients with seizure disorder requiring medication (such as steroids or anti-epileptics). 18. Patients undergoing renal dialysis. 19. Pregnancy or lactation.
研究者
相似试验
进行中（未招募）
不适用
A trial of upfront chemotherapy followed by surgical resection in patients witk biliary tract cancerResectable Biliary Tract CarcinomaMedDRA version: 18.0Level: LLTClassification code 10017621Term: Gallbladder carcinoma localizedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10034446Term: Periampullary carcinoma resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-002382-30-GBThe Clatterbridge Cancer Centre NHS Foundation Trust
已完成
不适用
A Phase II Study of Adjuvant Cisplatin and Gemsitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung CancerA Phase II Study of Adjuvant Cisplatin and Gemcitabine in patients with completely resected stage II-IIIA Non-Small Cell Lung CancerJPRN-UMIN000002855Toracic Medical Oncology of Toracic Center Cancer Instiute Hospital Japanese Foundation Cancer Reseach55
进行中（未招募）
不适用
Phase II Trial of Neoadjuvent Cisplatin, Gemcitabine and Sunitinib Malate followed by radical cystectomy for transitional Cell Carcinoma (TCC) of the bladderoperable bladder cancer (T2 to T4a) lymph node negative diseaseEUCTR2008-006214-26-GBHoosier Oncology Group46
已完成
不适用
Clinical phase II study of cisplatin plus gemcitabine followed by switch maintenance docetaxel for advanced squamous-cell lung cancerJPRN-UMIN000004297Okayama Lung Cancer Study Group40
已完成
不适用
Phase II trial of gemcitabine and cisplatin in patients with completely resected stage IB-IIIA non-small-cell lung cancer.JPRN-UMIN000000705First Department of Surgery Hamamatsu University School of Medicine20